Jane Street’s Precision BioSciences DTIL Stock Holding History

Jane Street’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81.7K	Buy	+10,400	New	+$73.2K	﹤0.01%	10713
2021 Q4	–	Sell	-410	Closed	-$142K	–	10198
2021 Q3	$142K	Sell	410 -53	-11%	-$18K	﹤0.01%	9093
2021 Q2	$174K	Buy	+463	New	+$139K	﹤0.01%	8927
2021 Q1	–	Sell	-523	Closed	-$131K	–	9175
2020 Q4	$131K	Buy	+523	New	+$128K	﹤0.01%	7122

Other funds holding DTIL

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Jane Street's DTIL Position: Q2 2026 in Review

Jane Street sold out of Precision BioSciences (DTIL) in Q2 2026, closing a stake of 18,993 shares — an estimated $134K sold.

Jane Street first reported a position in DTIL in Q4 2020 and held it in 9 quarters. The position peaked at $665K in Q2 2021. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

Jane Street reported no remaining Precision BioSciences position as of Q2 2026 after selling out during the quarter.
Jane Street sold 18,993 Precision BioSciences shares in Q2 2026, an estimated $134K.
Jane Street first reported a position in Precision BioSciences in Q4 2020 and held it in 9 quarters.
Jane Street's Precision BioSciences position peaked at $665K in Q2 2021.
95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.